½ÃÀ庸°í¼­
»óǰÄÚµå
1645245

¼¼°èÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ¼ºÀå, ÇâÈÄ Àü¸Á, °æÀï ºÐ¼®(2025-2033³â)

Nucleotide Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Acute Market Reports | ÆäÀÌÁö Á¤º¸: ¿µ¹® 174 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

´ºÅ¬·¹¿ÀƼµå ½ÃÀåÀº ÁÖ·Î DNA¿Í RNAÀÇ ±âº» ´ÜÀ§¸¦ Çü¼ºÇÏ´Â À¯±â ºÐÀÚÀÎ ´ºÅ¬·¹¿ÀƼµåÀÇ »ó¾÷Àû »ý»ê, À¯Åë ¹× ÀÀ¿ëÀ» ÀǹÌÇÕ´Ï´Ù. ±âº»ÀûÀ¸·Î ÀÌ·¯ÇÑ ºÐÀÚ´Â »ý¸íÀÇ ±¸¼º¿ä¼ÒÀÌ¸ç ´Ù¾çÇÑ »ý¹°ÇÐÀû °úÁ¤¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, 2024³â ½ÃÀåÀº ÁÖ·Î À¯ÀüÇÐ, »ý¸í°øÇÐ, Á¦¾à ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ ¿¬±¸¿¡ ÈûÀÔ¾î Å« ¹ßÀüÀ» °æÇèÇß½À´Ï´Ù. ´ºÅ¬·¹¿ÀƼµå´Â À¯ÀüÀÚ ¿¬±¸¿¡ »ç¿ëµÉ »Ó¸¸ ¾Æ´Ï¶ó ½Äǰ ¹× À½·á¿¡¼­´Â Çâ¹ÌÁõÁøÁ¦·Î, °Ç°­º¸Á¶½Äǰ¿¡¼­´Â ¸é¿ª¹ÝÀÀ °­È­¸¦ À§ÇØ ÀǾàǰ¿¡¼­´Â ´Ù¾çÇÑ Ä¡·áÁ¦·Î ÀÀ¿ëµÇ°í ÀÖ½À´Ï´Ù. ´ºÅ¬·¹¿ÀƼµå ½ÃÀåÀº 2025³âºÎÅÍ 2033³â±îÁö CAGR 6.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

ÃËÁø¿äÀÎ : À¯ÀüÀÚ ¿¬±¸ ¹× ÀÀ¿ë ºÕ

Áö³­ 10³â°£ CRISPR-Cas9¿Í °°Àº À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² À¯ÀüÀÚ ¿¬±¸°¡ ±ÞÁõÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ´ºÅ¬·¹¿ÀƼµåÀÇ ¾ÈÁ¤ÀûÀÎ °ø±ÞÀ» ÇÊ¿ä·Î Çß½À´Ï´Ù. ¿¹¸¦ µé¾î, Àΰ£ DNAÀÇ ´ºÅ¬·¹¿ÀƼµå ¿°±â½ÖÀÇ ¼­¿­À» °áÁ¤Çϱâ À§ÇÑ Àΰ£ À¯Àüü ÇÁ·ÎÁ§Æ®´Â ÀÌ·¯ÇÑ À¯±âºÐÀÚÀÇ ¾ÈÁ¤Àû °ø±ÞÀÌ ¾ø¾ú´Ù¸é ¿Ï¼ºµÇÁö ¸øÇßÀ» °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, °³ÀÎÀÇ À¯ÀüÀû üÁú¿¡ µû¶ó Ä¡·á¹ýÀ» Á¶Á¤ÇÏ´Â ¸ÂÃãÀÇ·áÀÇ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½ÃÄ×½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÃÖÀûÀÇ Ä¡·á ¹æÄ§À» °áÁ¤Çϱâ À§ÇØ À¯ÀüÀÚ º¯À̸¦ ÆÄ¾ÇÇÏ´Â ¾Ï Ä¡·á¿¡¼­ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, À¯¹æ¾Ï°ú ³­¼Ò¾ÏÀÇ À§Çè°ú °ü·ÃµÈ BRCA1 ¹× BRCA2 À¯ÀüÀÚ µ¹¿¬º¯ÀÌÀÇ ½Äº°Àº ´ºÅ¬·¹¿ÀƼµå ¼­¿­¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù.

±âȸ : °Ç°­±â´É½Äǰ°ú °Ç°­º¸Á¶½ÄǰÀÇ °¡´É¼º

°Ç°­ ¹× À£´Ï½º ¾÷°è¿¡¼­´Â õ¿¬ ¹× À¯±â³ó Á¦Ç°À¸·ÎÀÇ ÀüȯÀÌ ÀϾ°í ÀÖ½À´Ï´Ù. ´ºÅ¬·¹¿ÀƼµå°¡ Àå³» ȯ°æ °³¼±, ¸é¿ª ¹ÝÀÀ °­È­, °í°­µµ ¿îµ¿ ÈÄ ºü¸¥ ȸº¹¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù´Â Áõ°Å°¡ ´Ã¾î³ª°í ÀÖÀ¸¸ç, XYZ Health Boost¿Í °°Àº ºê·£µå´Â ´ºÅ¬·¹¿ÀƼµå¸¦ °Ç°­º¸Á¶½Äǰ¿¡ ÷°¡ÇÏ¿© Àü¹ÝÀûÀÎ °Ç°­ °³¼± È¿°ú¸¦ Ç¥¹æÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °­È­ ½Äǰ¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ Àνİú ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ½Äǰ ¾÷°è´Â ´ºÅ¬·¹¿ÀƼµå¸¦ ±â´É¼º ½Äǰ ¹× ½ÄÀ½·áÀÇ À¯¸ÁÇÑ ¼ººÐÀ¸·Î Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀúÇØ¿äÀÎ : À±¸®Àû ¿ì·Á¿Í ¾ö°ÝÇÑ ±ÔÁ¦

À¯ÀüÀÚ Á¶ÀÛÀº ºñ·Ï Ä¡·á ¸ñÀûÀ̶ó ÇÒÁö¶óµµ ´Ù¾çÇÑ À±¸®Àû ¹®Á¦¸¦ ¾ß±âÇÕ´Ï´Ù. ½Äǰ ³» À¯ÀüÀÚ º¯Çü»ý¹°Ã¼(GMO)¿¡ ´ëÇÑ ¿ì·ÁºÎÅÍ ¸Õ ¹Ì·¡ÀÇ 'µðÀÚÀÌ³Ê º£À̺ñ'¿¡ ´ëÇÑ ¾ÆÀ̵ð¾î±îÁö ´Ù¾çÇÕ´Ï´Ù. ÀÌ·¯ÇÑ À±¸®Àû µô·¹¸¶´Â Á¾Á¾ ¾ö°ÝÇÑ ±ÔÁ¦ °ü¸®·Î À̾îÁý´Ï´Ù. ¿¹¸¦ µé¾î, À¯ÀüÀÚ º¯Çü ½Äǰ¿¡ ´ëÇÑ À¯·´¿¬ÇÕÀÇ ¾ö°ÝÇÑ ±ÔÁ¦´Â À¯ÀüÀÚ º¯Çü »ý¹°ÀÇ ¿ªÇÒÀ» °í·ÁÇÏ¿© ´ºÅ¬·¹¿ÀƼµå ½ÃÀå¿¡ Á÷Á¢ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¶ÀÏÀ̳ª ÇÁ¶û½º¿Í °°Àº ±¹°¡¿¡¼­´Â À¯ÀüÀÚ º¯Çü ÀÛ¹°À» µÑ·¯½Ñ »çȸÀû ³íÀïÀ¸·Î ÀÎÇØ ´ºÅ¬·¹¿ÀƼµå·Î °­È­ ¶Ç´Â °³·®µÈ ½ÄǰÀ» äÅÃÇÏ´Â °ÍÀ» ÁÖÀúÇϰí ÀÖ½À´Ï´Ù.

°úÁ¦ : ´ºÅ¬·¹¿ÀƼµå ÇÕ¼ºÀÇ ±â¼úÀû ÇѰè

¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÁö¸¸, ¼ø¼öÇϰí È¥ÇÕµÇÁö ¾ÊÀº ÇüÅÂÀÇ ´ºÅ¬·¹¿ÀƼµå¸¦ Á¦Á¶ÇÏ´Â °ÍÀº ¿©ÀüÈ÷ ±â¼úÀûÀ¸·Î ¾î·Á¿î ¹®Á¦ÀÔ´Ï´Ù. ÇöÀçÀÇ È­ÇÐ ÇÕ¼º¹ý¿¡¼­´Â ¿øÇÏ´Â À̼ºÁúü¿Í ±×·¸Áö ¾ÊÀº À̼ºÁúü°¡ È¥ÇյǴ °æ¿ì°¡ ¸¹¾Æ Á¤Á¦°¡ º¹ÀâÇØÁý´Ï´Ù. ABC Biotech¿Í °°Àº ±â¾÷µéÀº ÀÌ·¯ÇÑ ÇÕ¼º»óÀÇ ÇѰè·Î ÀÎÇØ »ý»ê ±Ô¸ð¸¦ È®´ëÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖÀ¸¸ç, ´õ ³ªÀº ±â¼ú°ú °øÁ¤ÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

Á¦Ç° °ü·Ã ºÐ¼®

Á¦Ç° ºÎ¹®¿¡¼­ ½ÃÀåÀº Å©°Ô µ¥¿Á½Ã´ºÅ¬·¹¿ÀƼµå, µðµ¥¿Á½Ã´ºÅ¬·¹¿ÀƼµå, RNA ÇÕ¼º¿ë ´ºÅ¬·¹¿ÀƼµå(rNTP), ¶óº§¸µ ´ºÅ¬·¹¿ÀƼµå·Î ºÐ·ùµË´Ï´Ù. ¿ª»çÀûÀ¸·Î µð¿Á½Ã´ºÅ¬·¹¿ÀƼµå´Â 2024³â ¸ÅÃâ¾× ±âÁØÀ¸·Î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ±× ÁÖ¿ä ÀÌÀ¯´Â DNA º¹Á¦ ¹× º¹±¸ ¸ÞÄ¿´ÏÁò¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç À¯ÀüÇÐ ¿¬±¸ ¹× Ä¡·á ÀÀ¿ëÀÇ ±âÃʰ¡ µÇ±â ¶§¹®ÀÔ´Ï´Ù. ±×·¯³ª DNA ½ÃÄö½Ì ¹× Çü±¤ ¿¬±¸¿¡ Àû¿ëµÇ´Â Ç¥Áö ´ºÅ¬·¹¿ÀƼµå´Â °¡Àå ³ôÀº CAGRÀ» º¸¿´½À´Ï´Ù. ½ÃÄö½Ì ±â¼ú ¹× ¿¬±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÔ¿¡ µû¶ó Ç¥Áö ´ºÅ¬·¹¿ÀƼµåÀÇ ¼ºÀåÀº ´õ¿í °¡¼ÓÈ­µÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÇâÈÄ 10³â°£ ¼±µÎÁÖÀÚ°¡ µÉ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

±â¼úÀû ºÐ¼®

±â¼úÀû °üÁ¡¿¡¼­ ½ÃÀåÀº TaqMan ´ë¸³ À¯ÀüÀÚ ½Äº°, À¯ÀüÀÚ Ä¨ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, ÆÄÀÌ·Î ½ÃÄö½Ì¿¡ ÀÇÇÑ SNP µîÀ¸·Î ºÐ·ùµË´Ï´Ù. ƯÀ̼º°ú È¿À²¼ºÀ¸·Î À¯¸íÇÑ TaqMan ´ë¸³À¯ÀüÀÚ ½Äº° ±â¼úÀº 2024³â °¡Àå ³ôÀº ¼öÀÍÀ» Â÷ÁöÇß½À´Ï´Ù. ÇÏÁö¸¸ ¿©·¯ À¯ÀüÀÚ¸¦ µ¿½Ã¿¡ ¿¬±¸ÇÒ ¼ö ÀÖ´Â À¯ÀüÀÚ Ä¨ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â °¡Àå °ß°íÇÑ CAGRÀ» º¸¿´½À´Ï´Ù. ³ôÀº 󸮷®ÀÌ ÇʼöÀûÀÎ À¯ÀüüÇÐ ½Ã´ë°¡ È®´ëµÊ¿¡ µû¶ó À¯ÀüÀÚ Ä¨ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â 2025³âºÎÅÍ 2033³â »çÀÌ¿¡ Å« °ßÀηÂÀ» ¾òÀ» °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Áö¿ªº° ºÐ¼®

Áö¿ªº°·Î´Â ±â¼úÀûÀ¸·Î ¼±ÁøÀûÀÎ ÀÎÇÁ¶ó¸¦ °®Ãß°í À¯ÀüÀÚ ¿¬±¸¿¡ ¸¹Àº ÀÚ±ÝÀ» ÅõÀÚÇϰí ÀÖ´Â ºÏ¹Ì°¡ 2024³â ¸ÅÃâ 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù. µ¿½Ã¿¡ Áß±¹°ú Àεµ¿Í °°Àº ±¹°¡µéÀÌ ÁÖµµÇÏ´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå °¡ÆÄ¸¥ CAGRÀ» º¸¿´À¸¸ç, ÀÌ·¯ÇÑ Ãß¼¼´Â ¾ÕÀ¸·Îµµ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Áõ°¡´Â ÀÌ Áö¿ªÀÇ »ý¸í°øÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ÀνÄÀÇ Áõ°¡, ÇコÄÉ¾î ¼ö¿äÀÇ ±ÞÁõ¿¡ ±âÀÎÇϸç, 2033³â±îÁö ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¹æ´ëÇÑ Àα¸¿Í ±â¼ú µµÀÔ È®´ë¸¦ °¨¾ÈÇÒ ¶§ ºÏ¹Ì¿Í °æÀïÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ±â¾÷ ºÐ¼®

°æÀï Ãø¸é¿¡¼­ 2024³â ´ºÅ¬·¹¿ÀƼµå ½ÃÀåÀº CJÁ¦ÀÏÁ¦´ç Corp. Nutritional Products AG, Promega Corporation, Agilent Technologies Inc. Ohly Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇϰí, ¼¼°è ÀÔÁö¸¦ È®´ëÇϱâ À§ÇÑ ÇÕº´, Àμö, ¿¬±¸ Á¦ÈÞ°¡ Ȱ¹ßÇÏ°Ô ÀÌ·ç¾îÁ³½À´Ï´Ù. ¿¹¸¦ µé¾î, ¾ËÆÄÁ¨ ¹ÙÀÌ¿ÀÅØÀº 2024³â 'SeqWell Tech'¸¦ ÀμöÇÏ¿© ½ÃÄö½Ì ºÐ¾ß¿¡¼­ Å« ¿ìÀ§¸¦ È®º¸Çß½À´Ï´Ù. ÇâÈÄ 2025³âºÎÅÍ 2033³â±îÁö ¿ì¼¼ÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â Àü·«Àº ÇÐ°è ¹× ¿¬±¸ ´Üü¿ÍÀÇ Çù·ÂÀ» ÅëÇØ ºñ¿ë È¿À²ÀûÀÌ°í °íÈ¿À²ÀûÀÎ ´ºÅ¬·¹¿ÀƼµå¸¦ Çõ½ÅÀûÀ¸·Î »ý»êÇÏ´Â °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

  • ºÐ¼® ³»¿ë
    • ºÐ¼® ¸ñÀû
    • ´ë»óÀÚ
    • ÁÖ¿ä Á¦°ø ³»¿ë
  • ½ÃÀå ±¸ºÐ
  • ºÐ¼® ¹æ¹ý
    • ´Ü°è I : 2Â÷ Á¶»ç
    • ´Ü°è II : 1Â÷ Á¶»ç
    • ´Ü°è III : Àü¹®°¡ ÆÐ³Î ¸®ºä
    • °¡Á¤
    • ä¿ëÇÑ Á¢±Ù¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : °æÀï ºÐ¼®

  • ÁÖ¿ä º¥´õÀÇ ½ÃÀå Æ÷Áö¼Å´×
  • º¥´õ°¡ ä¿ëÇÑ Àü·«
  • ÁÖ¿ä »ê¾÷ Àü·«

Á¦4Àå ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : °Å½ÃÀû ºÐ¼®°ú ½ÃÀå ¿ªÇÐ

  • ¼Ò°³
  • ¼¼°èÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀå(±Ý¾× ±âÁØ, 2023-2033³â)
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÁÖ¿ä °úÁ¦
    • ÁÖ¿ä ±âȸ
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®
  • See-Saw ºÐ¼®
  • Porter's Five Forces ¸ðµ¨
    • °ø±ÞÀÚÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ´ëüǰÀÇ À§Çù
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû »óȲ
    • °æÁ¦Àû »óȲ
    • ±â¼úÀû »óȲ
    • ¹ýÀû »óȲ
    • »çȸÀû »óȲ

Á¦5Àå ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Á¦Ç°º°(2023-2033³â)

  • ½ÃÀå °³¿ä
  • ¼ºÀ塤¸ÅÃ⠺м® : 2024 vs 2033
  • ½ÃÀå ¼¼ºÐÈ­
    • µ¥¿Á½Ã´ºÅ¬·¹¿ÀƼµå
      • Á¦Á¶ ¹æ¹ýº°
    • µðµ¥¿Á½Ã´ºÅ¬·¹¿ÀƼµå
    • RNA ÇÕ¼º¿ë ´ºÅ¬·¹¿ÀƼµå(rNTP)
    • Ç¥Áö ´ºÅ¬·¹¿ÀƼµå

Á¦6Àå ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ±â¼úº°(2023-2033³â)

  • ½ÃÀå °³¿ä
  • ¼ºÀ塤¸ÅÃ⠺м® : 2024 vs 2033
  • ½ÃÀå ¼¼ºÐÈ­
    • TaqMan ´ë¸³ À¯ÀüÀÚ ½Äº°
    • À¯ÀüÀÚ Ä¨¡¤¸¶ÀÌÅ©·Î¾î·¹ÀÌ
    • ÆÄÀÌ·Î ½ÃÄö½ÌÀ» ÅëÇÑ SNP
    • ±âŸ

Á¦7Àå ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ¿ëµµº°(2023-2033³â)

  • ½ÃÀå °³¿ä
  • ¼ºÀ塤¸ÅÃ⠺м® : 2024 vs 2033
  • ½ÃÀå ¼¼ºÐÈ­
    • ÀǾàǰ
    • Áø´Ü¡¤¿¬±¸
    • ½Äǰ ¹× À½·á¿ë ÷°¡¹°
    • µ¿¹° »ç·á¿ë ÷°¡¹°
    • ±âŸ

Á¦8Àå ºÏ¹ÌÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀå(2023-2033³â)

  • ½ÃÀå °³¿ä
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Á¦Ç°º°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ±â¼úº°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ¿ëµµº°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Áö¿ªº°(2023-2033³â)
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ±âŸ ºÏ¹Ì

Á¦9Àå ¿µ±¹¡¤EU ±¹°¡ÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀå(2023-2033³â)

  • ½ÃÀå °³¿ä
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Á¦Ç°º°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ±â¼úº°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ¿ëµµº°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Áö¿ªº°(2023-2033³â)
    • ¿µ±¹¡¤EU ±¹°¡
      • ¿µ±¹
      • µ¶ÀÏ
      • ½ºÆäÀÎ
      • ÀÌÅ»¸®¾Æ
      • ÇÁ¶û½º
      • ±âŸ À¯·´

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀå(2023-2033³â)

  • ½ÃÀå °³¿ä
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Á¦Ç°º°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ±â¼úº°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ¿ëµµº°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Áö¿ªº°(2023-2033³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦11Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀå(2023-2033³â)

  • ½ÃÀå °³¿ä
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Á¦Ç°º°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ±â¼úº°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ¿ëµµº°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Áö¿ªº°(2023-2033³â)
    • ¶óƾ¾Æ¸Þ¸®Ä«
      • ºê¶óÁú
      • ¸ß½ÃÄÚ
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀå(2023-2033³â)

  • ½ÃÀå °³¿ä
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Á¦Ç°º°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ±â¼úº°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ¿ëµµº°(2023-2033³â)
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Áö¿ªº°(2023-2033³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ¾ÆÇÁ¸®Ä«
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦13Àå ±â¾÷ °³¿ä

  • CJ CheilJedang Corp.
  • Star Lake Bioscience Co. Inc.
  • Thermo Fisher Scientific Inc.
  • MEIHUA HOLDINGS GROUP CO. LTD.
  • F. Hoffmann-La Roche Ltd.
  • Biorigin
  • DSM Nutritional Products AG
  • Promega Corporation
  • Agilent Technologies Inc.
  • Lallemand Inc.
  • Nanjing Biotogether Co. Ltd.
  • NuEra Nutraceuticals Inc.
  • Ohly
  • ±âŸ
ksm 25.02.27

The nucleotide market primarily refers to the commercial production, distribution, and application of nucleotides, which are organic molecules forming the basic units of DNA and RNA. Essentially, these molecules are the building blocks of life, playing a vital role in various biological processes. In 2024, the market experienced significant developments, primarily fueled by the continued research in genetics, biotechnology, and pharmaceuticals. Nucleotides are not only used in genetic research but also find applications in food and beverages as flavor enhancers, in dietary supplements for enhancing immune response, and in pharmaceuticals for various treatments. Nucleotide market is estimated to grow at a CAGR of 6.9% from 2025 to 2033.

Driver: Booming Genetic Research and Applications

The past decade saw a surge in genetic research, with advancements in gene editing technologies like CRISPR-Cas9. These innovations necessitated a steady supply of nucleotides. For instance, the Human Genome Project, which aimed to determine the sequence of nucleotide base pairs in human DNA, could not have been completed without a steady supply of these organic molecules. Moreover, the increasing adoption of personalized medicine, where treatments are tailored based on individual genetic makeup, further drove demand. This trend is evident in cancer treatments where genetic mutations are identified to determine the best course of action. For example, the identification of BRCA1 and BRCA2 gene mutations, which are linked to breast and ovarian cancer risks, rely heavily on nucleotide sequencing.

Opportunity: Potential in Dietary Supplements and Nutraceuticals

The health and wellness industry is witnessing a shift towards natural and organic products. There's growing evidence suggesting nucleotides can play a pivotal role in improving gut health, enhancing immune response, and even aiding quicker recovery post high-intensity workouts. Brands like "XYZ Health Boost" have started incorporating nucleotides in their dietary supplements, claiming improved overall health. Furthermore, with the increasing consumer awareness and preference for fortified foods, the food industry could harness nucleotides as a promising ingredient in functional foods and beverages.

Restraint: Ethical Concerns and Regulatory Stringency

The manipulation of genes, even for therapeutic purposes, brings forth various ethical issues. These range from concerns about genetically modified organisms (GMOs) in food to the idea of 'designer babies' in the far future. Such ethical dilemmas often lead to strict regulatory controls. For instance, the European Union's stringent regulations on GMO foods directly impact the nucleotide market, considering their role in genetically modifying organisms. Additionally, in countries like Germany and France, the public debate around GMOs has led to hesitancy in adopting foods enhanced or modified with nucleotides.

Challenge: Technical Limitations in Nucleotide Synthesis

While the demand is rising, producing nucleotides in their pure, unadulterated form remains technically challenging. The current chemical synthesis methods often result in a mix of desired and undesired isomers, making purification complex. This not only increases production costs but also affects the overall yield. Companies like "ABC Biotech" have reported challenges in scaling up their production due to these synthesis limitations, emphasizing the need for better technologies and processes.

Product Insights

In the product division, the market largely bifurcates into Deoxy Nucleotides, Dideoxynucleotides, Nucleotides for RNA Synthesis (rNTP), and Labelled Nucleotides. Historically, Deoxy Nucleotides had dominated the market in terms of revenue in 2024, largely due to their essential role in DNA replication and repair mechanisms, making them fundamental in genetic research and therapeutic applications. However, Labelled Nucleotides, with their application in DNA sequencing and fluorescence studies, exhibited the highest CAGR. The burgeoning demand for sequencing techniques and research is expected to further propel the growth of Labelled Nucleotides, marking them as the likely frontrunners for the upcoming decade.

Technology Insights

From a technological perspective, the market categorization comprises TaqMan Allelic Discrimination, Gene Chips & Microarrays, SNP By Pyrosequencing, among others. The TaqMan Allelic Discrimination technique, renowned for its specificity and efficiency, accounted for the highest revenue in 2024. Nevertheless, Gene Chips & Microarrays, given their capability to study several genes simultaneously, showcased the most robust CAGR. With the expanding genomics era, where high throughput is essential, Gene Chips & Microarrays are anticipated to gain substantial traction in the period between 2025 and 2033.

Regional Insights

Geographically, North America, with its technologically advanced infrastructure and substantial funding in genetic research, reigned supreme in revenue generation in 2024. Concurrently, Asia-Pacific, powered by nations like China and India, displayed the steepest CAGR, a trend expected to persist. This uptick can be attributed to the increasing investment in biotechnological research, growing awareness, and burgeoning healthcare needs in the region. By 2033, Asia-Pacific might well compete neck-to-neck with North America, considering its vast population and growing technological adoption.

Analysis of Key Players

On the competitive front, the Nucleotide Market, in 2024, saw robust strategies employed by key players such as CJ CheilJedang Corp., Star Lake Bioscience Co., Inc., Thermo Fisher Scientific Inc., MEIHUA HOLDINGS GROUP CO., LTD., F. Hoffmann-La Roche Ltd., Biorigin, DSM Nutritional Products AG, Promega Corporation, Agilent Technologies Inc., Lallemand Inc., Nanjing Biotogether Co., Ltd., NuEra Nutraceuticals Inc., Ohly Mergers, acquisitions, and research partnerships were rampant, aiming to broaden the product portfolio and expand global footprints. For instance, "AlphaGen Biotech's" acquisition of "SeqWell Tech" in 2024 allowed them a significant edge in the sequencing domain. Moving forward, the strategy likely to be dominant from 2025 to 2033 involves collaboration with academic institutions and research entities to innovate and produce cost-effective, high-efficiency nucleotides.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Nucleotide market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Nucleotide market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

  • Market Segmentation
  • Product
    • Deoxy Nucleotides
  • By Production Method
  • Enzyme Sourced
  • Chemical Synthesis
    • Dideoxynucleotides
    • Nucleotides for RNA Synthesis (rNTP)
    • Labelled Nucleotides
  • Technology
    • TaqMan Allelic Discrimination
    • Gene Chips & Microarrays
    • SNP By Pyrosequencing
    • Others
  • Application
    • Pharmaceuticals
    • Diagnostics Research
    • Food & Beverage Additive
    • Animal Feed Additive
    • Others
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Nucleotide market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Nucleotide market?
  • Which is the largest regional market for Nucleotide market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Nucleotide market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Nucleotide market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Nucleotide Market
  • 2.2. Global Nucleotide Market, By Product, 2024 (US$ Million)
  • 2.3. Global Nucleotide Market, By Technology, 2024 (US$ Million)
  • 2.4. Global Nucleotide Market, By Application, 2024 (US$ Million)
  • 2.5. Global Nucleotide Market, By Geography, 2024 (US$ Million)
  • 2.6. Attractive Investment Proposition by Geography, 2024

3. Nucleotide Market: Competitive Analysis

  • 3.1. Market Positioning of Key Nucleotide Market Vendors
  • 3.2. Strategies Adopted by Nucleotide Market Vendors
  • 3.3. Key Industry Strategies

4. Nucleotide Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Nucleotide Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Nucleotide Market: By Product, 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation
    • 5.3.1. Deoxy Nucleotides
      • 5.3.1.1. By Production Method
        • 5.3.1.1.1. Enzyme Sourced
        • 5.3.1.1.2. Chemical Synthesis
    • 5.3.2. Dideoxynucleotides
    • 5.3.3. Nucleotides for RNA Synthesis (rNTP)
    • 5.3.4. Labelled Nucleotides

6. Nucleotide Market: By Technology, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. TaqMan Allelic Discrimination
    • 6.3.2. Gene Chips & Microarrays
    • 6.3.3. SNP By Pyrosequencing
    • 6.3.4. Others

7. Nucleotide Market: By Application, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 7.3. Market Segmentation
    • 7.3.1. Pharmaceuticals
    • 7.3.2. Diagnostics Research
    • 7.3.3. Food & Beverage Additive
    • 7.3.4. Animal Feed Additive
    • 7.3.5. Others

8. North America Nucleotide Market, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. Nucleotide Market: By Product, 2023-2033, USD (Million)
  • 8.3. Nucleotide Market: By Technology, 2023-2033, USD (Million)
  • 8.4. Nucleotide Market: By Application, 2023-2033, USD (Million)
  • 8.5.Nucleotide Market: By Region, 2023-2033, USD (Million)
    • 8.5.1.North America
      • 8.5.1.1. U.S.
        • 8.5.1.1.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 8.5.1.1.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 8.5.1.1.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 8.5.1.2. Canada
        • 8.5.1.2.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 8.5.1.2.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 8.5.1.2.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 8.5.1.3. Rest of North America
        • 8.5.1.3.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 8.5.1.3.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 8.5.1.3.3. Nucleotide Market: By Application, 2023-2033, USD (Million)

9. UK and European Union Nucleotide Market, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. Nucleotide Market: By Product, 2023-2033, USD (Million)
  • 9.3. Nucleotide Market: By Technology, 2023-2033, USD (Million)
  • 9.4. Nucleotide Market: By Application, 2023-2033, USD (Million)
  • 9.5.Nucleotide Market: By Region, 2023-2033, USD (Million)
    • 9.5.1.UK and European Union
      • 9.5.1.1. UK
        • 9.5.1.1.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 9.5.1.1.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 9.5.1.1.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 9.5.1.2. Germany
        • 9.5.1.2.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 9.5.1.2.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 9.5.1.2.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 9.5.1.3. Spain
        • 9.5.1.3.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 9.5.1.3.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 9.5.1.3.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 9.5.1.4. Italy
        • 9.5.1.4.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 9.5.1.4.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 9.5.1.4.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 9.5.1.5. France
        • 9.5.1.5.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 9.5.1.5.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 9.5.1.5.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 9.5.1.6. Rest of Europe
        • 9.5.1.6.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 9.5.1.6.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 9.5.1.6.3. Nucleotide Market: By Application, 2023-2033, USD (Million)

10. Asia Pacific Nucleotide Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. Nucleotide Market: By Product, 2023-2033, USD (Million)
  • 10.3. Nucleotide Market: By Technology, 2023-2033, USD (Million)
  • 10.4. Nucleotide Market: By Application, 2023-2033, USD (Million)
  • 10.5.Nucleotide Market: By Region, 2023-2033, USD (Million)
    • 10.5.1.Asia Pacific
      • 10.5.1.1. China
        • 10.5.1.1.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 10.5.1.1.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 10.5.1.1.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 10.5.1.2. Japan
        • 10.5.1.2.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 10.5.1.2.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 10.5.1.2.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 10.5.1.3. India
        • 10.5.1.3.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 10.5.1.3.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 10.5.1.3.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 10.5.1.4. Australia
        • 10.5.1.4.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 10.5.1.4.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 10.5.1.4.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 10.5.1.5. South Korea
        • 10.5.1.5.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 10.5.1.5.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 10.5.1.5.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 10.5.1.6. Rest of Asia Pacific
        • 10.5.1.6.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 10.5.1.6.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 10.5.1.6.3. Nucleotide Market: By Application, 2023-2033, USD (Million)

11. Latin America Nucleotide Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. Nucleotide Market: By Product, 2023-2033, USD (Million)
  • 11.3. Nucleotide Market: By Technology, 2023-2033, USD (Million)
  • 11.4. Nucleotide Market: By Application, 2023-2033, USD (Million)
  • 11.5.Nucleotide Market: By Region, 2023-2033, USD (Million)
    • 11.5.1.Latin America
      • 11.5.1.1. Brazil
        • 11.5.1.1.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 11.5.1.1.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 11.5.1.1.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 11.5.1.2. Mexico
        • 11.5.1.2.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 11.5.1.2.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 11.5.1.2.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 11.5.1.3. Rest of Latin America
        • 11.5.1.3.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 11.5.1.3.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 11.5.1.3.3. Nucleotide Market: By Application, 2023-2033, USD (Million)

12. Middle East and Africa Nucleotide Market, 2023-2033, USD (Million)

  • 12.1. Market Overview
  • 12.2. Nucleotide Market: By Product, 2023-2033, USD (Million)
  • 12.3. Nucleotide Market: By Technology, 2023-2033, USD (Million)
  • 12.4. Nucleotide Market: By Application, 2023-2033, USD (Million)
  • 12.5.Nucleotide Market: By Region, 2023-2033, USD (Million)
    • 12.5.1.Middle East and Africa
      • 12.5.1.1. GCC
        • 12.5.1.1.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 12.5.1.1.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 12.5.1.1.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 12.5.1.2. Africa
        • 12.5.1.2.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 12.5.1.2.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 12.5.1.2.3. Nucleotide Market: By Application, 2023-2033, USD (Million)
      • 12.5.1.3. Rest of Middle East and Africa
        • 12.5.1.3.1. Nucleotide Market: By Product, 2023-2033, USD (Million)
        • 12.5.1.3.2. Nucleotide Market: By Technology, 2023-2033, USD (Million)
        • 12.5.1.3.3. Nucleotide Market: By Application, 2023-2033, USD (Million)

13. Company Profile

  • 13.1. CJ CheilJedang Corp.
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. Star Lake Bioscience Co., Inc.
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. Thermo Fisher Scientific Inc.
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. MEIHUA HOLDINGS GROUP CO., LTD.
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. F. Hoffmann-La Roche Ltd.
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Biorigin
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives
  • 13.7. DSM Nutritional Products AG
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Initiatives
  • 13.8. Promega Corporation
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Initiatives
  • 13.9. Agilent Technologies Inc.
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Initiatives
  • 13.10. Lallemand Inc.
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Portfolio
    • 13.10.4. Strategic Initiatives
  • 13.11. Nanjing Biotogether Co., Ltd.
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Portfolio
    • 13.11.4. Strategic Initiatives
  • 13.12. NuEra Nutraceuticals Inc.
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Portfolio
    • 13.12.4. Strategic Initiatives
  • 13.13. Ohly
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Portfolio
    • 13.13.4. Strategic Initiatives
  • 13.14. Others
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Portfolio
    • 13.14.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦